WO1994002103A2 - Ovulationshemmendes mittel zur hormonalen kontrazeption - Google Patents
Ovulationshemmendes mittel zur hormonalen kontrazeption Download PDFInfo
- Publication number
- WO1994002103A2 WO1994002103A2 PCT/DE1993/000656 DE9300656W WO9402103A2 WO 1994002103 A2 WO1994002103 A2 WO 1994002103A2 DE 9300656 W DE9300656 W DE 9300656W WO 9402103 A2 WO9402103 A2 WO 9402103A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- estrogen
- component
- daily units
- progestogen
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the invention relates to an ovulation-inhibiting agent for hormonal contraception according to the preamble of patent claim 1.
- Combination preparations and sequence preparations are known on the one hand as hormonal ovulation inhibitors to be taken orally in daily units.
- the desired cycle duration is 28 days
- B. can be natural estrogen or synthetic ethinyl estradiol and after taking the aforementioned 21 daily units there is a seven-day break in which there is a withdrawal bleeding simulating the natural menstrual period.
- substitution preparations were hormones administered during the entire cycle, for example in the sequence 10 days of estrogen preparation, 11 days of combination of estrogen and progestogen preparation, 7 days of estrogen preparation in particularly low doses, but these substitution preparations are not suitable for inhibiting ovulation .
- the sequence preparations used in substitution therapy are particularly unsuitable for contraception because the natural estradiol in the given dose does not prevent ovulation and the phase in which progestin is administered is too short with only eleven days is.
- the sequential arrangement described above ensures a relatively good cycle control in the substitution preparations.
- the three most important aspects to be considered in hormonal contraception are contraceptive safety, good cycle control and a minimum of side effects.
- the contraceptive safety is based primarily on the effects of the progestogen component; it is used in a known preparation in a dose which is approximately twice as high as the dose necessary for inhibiting ovulation.
- progestogen is available in sufficient oral dosage in modern oral contraceptives to ensure reliable contraception.
- the synthetic estrogen ethinyl estradiol normally used further enhances the ovulation-inhibiting effect of the gestagen.
- estradiol is not very suitable for use in combination products.
- the progestogen component ensures reliable contraceptive protection; but progestogen by stimulation local enzymes causes an increased inactivation of the estradiol in the endometrium and the estrogen effect on the endometrium is greatly reduced, there is a frequent bleeding with the adverse effects already described.
- ethinyl estradiol is metabolized much more slowly in the endometrium and accordingly has a sufficient effect on the endometrium.
- an ovulation-inhibiting agent of the generic type is known from US Pat. No. 4,921,843, in which between the ingestion of the last of the hormone daily units, such as dragées, tablets or the like, the second hormone component is a break in intake of at least one day, preferably of two days, which can be bridged by a placebo, for example, before a new daily hormone unit, namely the first of the first hormone components of the next cycle, is taken.
- a new daily hormone unit namely the first of the first hormone components of the next cycle
- DE-OS 26 45 307 Even with a means known from DE-OS 26 45 307 for treating climacteric failure symptoms, there is a pause in taking or at least the simulation of a Intake pause due to the temporary use of a particularly weak type of estrogen which, unlike the generic agent, does not cause a sufficient disturbance in follicular maturation, is considered necessary. Overall, the hormone doses used, in particular also the duration of the gestagen phase, are not sufficient for the contraceptive agent described in the above-mentioned publication.
- DE-OS 24 31 704 also describes a means for alleviating climacteric complaints, in which fluctuating estrogen concentrations are provided. The progestogen only starts after the middle of the cycle, so that no contraceptive effect can be achieved. In addition, a hormone-free intake break is mandatory.
- EP-OS 0 368 373 describes an ovulation-inhibiting agent in which a constant progestogen level is provided over the entire cycle duration and the estrogen phases are cyclically superimposed on it.
- the disadvantage here is that there is an increased risk of intermenstrual bleeding and the continuous progestogen intake has a good contraceptive effect, but * also has a permanent vasoconstricting effect, so that especially in women with a tendency to circulatory disorders, for example with increasing age, health disadvantages cannot be excluded.
- the invention is based on the object of further developing the ovulation-inhibiting agent of the generic type in such a way that, with a high level of contraceptive safety, better cycle control is achieved with the further avoidance of intermenstrual bleeding and side effects are avoided.
- Preferred embodiments of the invention are the subject of claims 2 to 24.
- the invention is based on the surprising finding that it is possible to improve the contraceptive safety and the cycle control in that, on the one hand, hormonal control is caused by an early disruption of follicular maturation within the hormone-neutral pause that was previously usual, namely by the estrogen component to be taken of follicular events over the entire cycle. Due to the fact that in the pure estrogen phase, similar to the naturally occurring conditions, an adequate build-up of mucous membrane first occurs, bleeding occurs on the other hand even with a lower dosage of the hormone components in the actual ovulation inhibition phase. in which a combination of estrogen and progestin is administered is much less common.
- the pure estrogen phase is at least five days and can be extended to up to ten days if natural estrogen is used and up to 14 days if synthetic estrogen is used, depending on the desired cycle duration, which generally follows a longer combination phase.
- the pure estrogen phase at the beginning of the inventive treatment enables a sufficient proliferatior. of the endometrium.
- Reliable contraceptive protection is achieved in particular if, as is preferably proposed according to the invention, the progestogen is administered in the subsequent combination phase in the individual daily units in a double ovulation dose. After taking the last progestogen-containing tablet, the next the estrogen phase for withdrawal bleeding, while at the same time the re-proliferation of the endometrium is started by taking the estrogen.
- the embodiment of the invention in which only natural estrogen is used is of particular advantage, since particularly low side effects are to be expected with sufficient contraceptive safety and cycle control.
- the ovulation-inhibiting agent according to the invention is used in such a way that, for hormonal contraception within the desired cycle, a certain number of daily hormone units, such as doses, tablets or the like, of the first hormone component, which act essentially as a hormone-active substance, are consecutively contains only one estrogen preparation, and then the second hormone component, which in combination contains an estrogen and a gestagen preparation at least in doses sufficient to inhibit ovulation, are administered orally, the day after the administration of the last of the daily units of second hormone component of the cycle in question, the first of the day units of the first hormone component of the next cycle is administered, so that one hormone daily unit is taken every day with the exclusion of pauses in taking.
- a certain number of daily hormone units such as doses, tablets or the like
- the first hormone component which act essentially as a hormone-active substance
- the second hormone component which in combination contains an estrogen and a gestagen preparation at least in doses sufficient to inhibit ovulation
- the bleeding that occurs when using the ovulation-inhibiting agent according to the invention is associated with less blood loss and is less painful, due to the continuous administration of estrogen, than with the ovulation-inhibiting agent according to the prior art, from which the invention proceeds as a genus.
- Contraceptive security is also significantly higher because there are no tablet-free days, not even one on which which could otherwise be breached by natural hormone processes, the contraceptive security. Because of the constant estrogen supply, there is also a continuously positive vasodilating effect, which means that circulatory disorders can be counteracted.
- a further advantage of the ovulation-inhibiting agent according to the invention is that, when used, the so-called prenstrual syndrome is suppressed, which can occur in a disadvantageous manner when the estrogen is discontinued for even one or a few days, as in the natural course of the cycle.
- the uniform estrogen level that is achieved when using the ovulation-inhibiting agent according to the invention also avoids the drop and increase in coagulation parameters during the hormone-free days or after restarting the intake in the next cycle. the coagulation system in an unstable equilibrium would otherwise be disturbed. Therefore, the ovulation-inhibiting agent according to the invention is particularly suitable for women over the age of forty, for whom it is known that the risk of circulatory disorders increases with age.
- the agent according to the invention in contrast to such cases, it is practice in which a woman occasionally takes known ovulation-inhibiting agents in immediate succession without interruption of intake for two or more menstrual cycles.
- B. in athletes mostly ⁇ ten ⁇ lies in the fact that the occurrence of menstrual bleeding at a certain point in time is characteristic, that bleeding occurs in each case while taking the estrogen component, that is, even if agents with several sequences of alternating estrogen and estrogen Progestagen components are taken approximately every four weeks. This is a special feature of the invention.
- agent according to the invention for contraception is also within the scope of the inventive concept, in contrast to agents of the type discussed at the outset, which are used to reduce climacteric complaints, etc.
- a sequence preparation was used for the ovulation-inhibiting treatment, which contained 7 daily units each with 2 mg estradiol and 21 daily units each with 4 mg oestradiol and 1 mg norethisterone acetate.
- the agent was administered over a year and, with very good contraceptive safety, showed practically no side effects, with intermenstrual bleeding occurring significantly less frequently than with conventional low-dose preparations.
- an ovulation-inhibiting agent in the form of a sequence preparation was used, which comprises 7 daily units with 4 mg ostradiol valerate each and 21 daily units with 4 mg ostradiol valerate each and 2 mg chlormadinone acetate.
- the mode of action corresponded to that of Example 1.
- An ovulation-inhibiting agent was used, which consists of 10 daily units, each with 20 ⁇ g of ethinyl estradiol and
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU45583/93A AU4558393A (en) | 1992-07-24 | 1993-07-26 | Ovulation inhibitor for hormonal contraception |
EP93915661A EP0651644A1 (de) | 1992-07-24 | 1993-07-26 | Ovulationshemmendes mittel zur hormonalen kontrazeption |
JP6504082A JPH07509454A (ja) | 1992-07-24 | 1993-07-26 | ホルモン避妊のための***抑止剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4224534A DE4224534A1 (de) | 1992-07-24 | 1992-07-24 | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
DEP4224534.6 | 1992-07-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994002103A2 true WO1994002103A2 (de) | 1994-02-03 |
WO1994002103A3 WO1994002103A3 (de) | 1994-05-11 |
Family
ID=6464040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1993/000656 WO1994002103A2 (de) | 1992-07-24 | 1993-07-26 | Ovulationshemmendes mittel zur hormonalen kontrazeption |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0651644A1 (de) |
JP (1) | JPH07509454A (de) |
AU (1) | AU4558393A (de) |
CA (1) | CA2140011A1 (de) |
DE (1) | DE4224534A1 (de) |
WO (1) | WO1994002103A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0696454A3 (de) * | 1994-08-12 | 1996-07-17 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
US6723351B2 (en) | 1997-11-10 | 2004-04-20 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
US7871994B2 (en) | 2001-01-11 | 2011-01-18 | Bayer Schering Pharma Ag | Hormone replacement therapy method and its administration form |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19504227C2 (de) * | 1995-02-09 | 1999-04-29 | Klaus Dr Med Umbreit | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
WO1998004267A1 (en) * | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
PT1293210E (pt) * | 2001-05-23 | 2004-04-30 | Pantarhei Bioscience Bv | Dispositivo e metodo anticoncepcional hormonal |
SI1453521T1 (sl) | 2001-12-05 | 2013-11-29 | Teva Women's Health, Inc. | Oralni kontraceptiki za preprečevanje nosečnosti in zmanjševanje predmenstrualne simptomatike |
CA2771944A1 (en) * | 2003-07-16 | 2005-01-27 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
DE102004026671A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Darreichungsform zur hormonalen Kontrazeption |
DE102004026670A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0499348A1 (de) * | 1991-02-09 | 1992-08-19 | Ehrlich, Marika, Dr. med. | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
-
1992
- 1992-07-24 DE DE4224534A patent/DE4224534A1/de not_active Ceased
-
1993
- 1993-07-26 CA CA002140011A patent/CA2140011A1/en not_active Abandoned
- 1993-07-26 JP JP6504082A patent/JPH07509454A/ja active Pending
- 1993-07-26 WO PCT/DE1993/000656 patent/WO1994002103A2/de not_active Application Discontinuation
- 1993-07-26 AU AU45583/93A patent/AU4558393A/en not_active Abandoned
- 1993-07-26 EP EP93915661A patent/EP0651644A1/de not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0499348A1 (de) * | 1991-02-09 | 1992-08-19 | Ehrlich, Marika, Dr. med. | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0696454A3 (de) * | 1994-08-12 | 1996-07-17 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
US6723351B2 (en) | 1997-11-10 | 2004-04-20 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
US6855339B2 (en) | 1997-11-10 | 2005-02-15 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
US6861076B2 (en) | 1997-11-10 | 2005-03-01 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
US6884439B2 (en) | 1997-11-10 | 2005-04-26 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
US6982096B2 (en) | 1997-11-10 | 2006-01-03 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
US7879364B2 (en) | 1997-11-10 | 2011-02-01 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
US8273379B2 (en) | 1997-11-10 | 2012-09-25 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
US7871994B2 (en) | 2001-01-11 | 2011-01-18 | Bayer Schering Pharma Ag | Hormone replacement therapy method and its administration form |
Also Published As
Publication number | Publication date |
---|---|
CA2140011A1 (en) | 1994-01-25 |
JPH07509454A (ja) | 1995-10-19 |
WO1994002103A3 (de) | 1994-05-11 |
EP0651644A1 (de) | 1995-05-10 |
DE4224534A1 (de) | 1994-01-27 |
AU4558393A (en) | 1994-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0499348B1 (de) | Ovulationshemmendes Mittel zur hormonalen Kontrazeption | |
EP0735881B1 (de) | Mittel und verfahren zur hormonalen kontrazeption und/oder zur aknebehandlung | |
DE19739916C2 (de) | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen | |
EP0835114B1 (de) | Pharmazeutisches kombinationspräparat, kit und methode zur hormonalen kontrazeption | |
EP0696454B1 (de) | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente | |
EP0628312B1 (de) | Kombinationspräparat zur Kontrazeption | |
EP0750501B1 (de) | Pharmazeutisches kombinationspräparat zur hormonalen kontrazeption | |
DE69729956T2 (de) | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält | |
WO1994002103A2 (de) | Ovulationshemmendes mittel zur hormonalen kontrazeption | |
WO1998035682A1 (de) | Mittel zur hormonalen kontrazeption und/oder behandlung und/oder prophylaxe von tumoren der brustdrüsen mit drei hormonkomponente | |
DE19549264A1 (de) | Verfahren und Kit zur Kontrazeption | |
EP0871453B1 (de) | Pharmazeutisches kombinationspräparat zur hormonalen kontrazeption | |
WO1996012494A1 (de) | Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle | |
EP0710111B1 (de) | Hormonales mittel zur therapie der akne und dessen verwendung | |
DE69827017T2 (de) | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung | |
DE4405591C1 (de) | Mittel zur postmenopausalen Hormonsubstitution | |
WO2006087173A1 (de) | Pharmazeutisches präparat zur kontrazeption | |
DE4216004B4 (de) | Verwendung kompetitiver Progesteronantagonisten | |
WO1997033589A1 (de) | Sequentielle estrogen/progesteronantagonist-kombination für die hormonersatz-therapie | |
WO1996028165A1 (de) | Einmonatsspritze als depot-kontrazeptivum und für die hormonersatztherapie für peri- und praemenopausale frauen | |
DE4406915A1 (de) | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA FI HU JP NO RU UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993915661 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2140011 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1995 374595 Country of ref document: US Date of ref document: 19950414 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1993915661 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993915661 Country of ref document: EP |